Metis TechBio Co (FRA:RO9) Shares Outstanding (EOP): 1,152.51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RO9 Metis TechBio Co Ltd FRA:RO9
17 GF Score
Price €1.28
! 1 Warning Sign
View Full Analysis

What is Metis TechBio Co Shares Outstanding (EOP)?

Metis TechBio Co FRA:RO9 +7.99% 17 Shares Outstanding (EOP) is 1,152.51 Mil as of Dec. 2025. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Metis TechBio Co's shares outstanding for the quarter that ended in Dec. 2025 was 1,152.51 Mil.

Metis TechBio Co's quarterly shares outstanding stayed the same from Sep. 2025 (1,152.51 Mil) to Dec. 2025 (1,152.51 Mil).

Metis TechBio Co's annual shares outstanding stayed the same from Dec. 2024 (1,152.51 Mil) to Dec. 2025 (1,152.51 Mil).


Metis TechBio Co  (FRA:RO9) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Metis TechBio Co Shares Outstanding (EOP) Related Terms


Metis TechBio Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Metis TechBio Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metis TechBio Co Shares Outstanding (EOP) Chart

Metis TechBio Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
1,152.51 1,152.51 1,152.51 1,152.51

Metis TechBio Co Quarterly Data
Dec22 Dec23 Dec24 Sep25 Dec25
Shares Outstanding (EOP) 1,152.51 1,152.51 1,152.51 1,152.51 1,152.51

FRA:RO9 vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Metis TechBio Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metis TechBio Co Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metis TechBio Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Metis TechBio Co's Shares Outstanding (EOP) falls into.


FRA:RO9
17GF Score
Metis TechBio Co Ltd FRA:RO9
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metis TechBio Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 1,152.51 Mil mean?
Metis TechBio Co (FRA:RO9) has a Shares Outstanding (EOP) of 1,152.51 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Metis TechBio Co and its competitors.
Is Metis TechBio Co's Shares Outstanding (EOP) too high?
Metis TechBio Co's current Shares Outstanding (EOP) is 1,152.51 Mil. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Shares Outstanding (EOP) compare to VRTX and REGN?
Metis TechBio Co's Shares Outstanding (EOP) of 1,152.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Metis TechBio Co and its competitors. Metis TechBio Co's current Shares Outstanding (EOP) is 1,152.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Shares Outstanding (EOP) of 1,152.51 Mil. The current Shares Outstanding (EOP) is 1,152.51 Mil. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Shares Outstanding (EOP) is 1,152.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metis TechBio Co Business Description

Other Exchanges 07666:Hong Kong
Address No. 21 Tianhe West Road, Room 201, 2nd Floor, Building 13, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing, CHN
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score

Get the complete analysis for FRA:RO9

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.28
Price